Home Cart Sign in  
Chemical Structure| 1797983-09-5 Chemical Structure| 1797983-09-5

Structure of GSK-J4 HCl
CAS No.: 1797983-09-5

Chemical Structure| 1797983-09-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50 values of 8.6 μM and 6.6 μM, respectively. It inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM and is a cell-permeable proagent of GSK-J1.

Synonyms: GSK-J4 (hydrochloride); GSK-J4 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK-J4 HCl

CAS No. :1797983-09-5
Formula : C24H28ClN5O2
M.W : 453.96
SMILES Code : O=C(OCC)CCNC1=NC(C2=NC=CC=C2)=NC(N3CCC4=CC=CC=C4CC3)=C1.[H]Cl
Synonyms :
GSK-J4 (hydrochloride); GSK-J4 hydrochloride
MDL No. :MFCD26142638
InChI Key :TYXWLTBYINKVNT-UHFFFAOYSA-N
Pubchem ID :71729974

Safety of GSK-J4 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of GSK-J4 HCl

epigenetics

Isoform Comparison

Biological Activity

Target
  • KDM6

    JMJD3, IC50:60 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
WT EpdSCs 10 μM 24 h prevented H3K27me3 loss and differentiation PMC7343604
SOX2+ EpdSCs 10 μM 24 h prevented H3K27me3 loss and differentiation PMC7343604
neuroblastoma cell lines 1 μM 72 h To evaluate the sensitivity of neuroblastoma cells to GSK-J4, results showed that some cells were highly sensitive to GSK-J4, with significantly reduced cell viability. PMC6200133
IMR5 cells 1 μM 72 h To analyze the gene expression changes in IMR5 cells treated with GSK-J4 through RNA sequencing, results showed that more than 7000 genes were significantly altered. PMC6200133
K562 cells 5 μM 24 h Restored H3K27me3 levels PMC10760961
K562 cells 5 μM 72 h Inhibited cell proliferation PMC10760961
OCI-AML5 cells 5 μM 24, 48, 72 h Increased H3K27me3 levels and decreased GATA2 and MEIS1 expression PMC10760961
ER-Hoxb8 cells 5 µM 3 days GSK-J4 treatment significantly decreased S100a8 and S100a9 mRNA levels in WT ER-Hoxb8 cells, while the effects on C/EBPδ KO cells were negligible PMC9122501
lung cancer cells 1 µM 5 days GSK-J4 was more toxic in SMARCA4-defective lung cancer cells, with a five-fold lower EC50 than in MYCamp cells PMC8280185
ovarian cancer cells 1 µM 5 days GSK-J4 strongly suppressed cell viability and clonogenic capability in SMARCA4-defective ovarian cancer cells PMC8280185
osteoprogenitors 1 μM 30 min GSK-J4 blocked the activation of MKP-1 by dexamethasone and restored the protein levels of p-JNK, p-ERK, p-p38, and PCNA, indicating that GSK-J4 alleviates the inhibitory effect of dexamethasone on osteoprogenitor proliferation by inhibiting H3K27me3 demethylation. PMC11604782
SF8628 K27M DIPG cells 6 μM 6, 24, 48, 72 h GSK-J4 significantly reduced the expression of DNA DSB repair genes and DNA accessibility, inhibiting DNA DSB repair. PMC6744979
DIPG-007 K27M DIPG cells 6 μM 6, 24, 48, 72 h GSK-J4 significantly reduced the expression of DNA DSB repair genes and DNA accessibility, inhibiting DNA DSB repair. PMC6744979
SF9427 H3 wild-type GBM cells 6 μM 72 h GSK-J4 did not alter the expression of DNA DSB repair genes in H3 wild-type GBM cells. PMC6744979
143B cells 15 μM 72 h To evaluate the effect of GSK-J4 on 143B cells, the results showed that GSK-J4 treatment increased H3K27me3 levels and enhanced the sensitivity of cells to cisplatin. PMC6335728
HOS cells 15 μM 72 h To evaluate the effect of GSK-J4 on HOS cells, the results showed that GSK-J4 treatment increased H3K27me3 levels and enhanced the sensitivity of cells to cisplatin. PMC6335728

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice tumor model intraperitoneal injection 10 mg/kg daily for five days prevented tumor differentiation PMC7343604
Mice Nestin-GFP mice Intraperitoneal injection 100 mg/kg Daily for 2 weeks To investigate the effect of GSK-J4 on the number of Nestin-GFP positive cells, results showed that GSK-J4 significantly increased the number of Nestin-GFP positive cells. PMC5670205
Mice KRAS+/Trp53-null lung cancer model Intraperitoneal injection 100 mg/kg Once daily for 10 days GSK-J4 inhibits the growth of Ezh2-deficient tumors. PMC9859827
mice CHLA20 and IMR32 xenograft models intraperitoneal injection 100 mg/kg 5 days/week, throughout the experiment To evaluate the antitumor activity of GSK-J4 in vivo, results showed that GSK-J4 significantly inhibited tumor growth and induced tumor regression. PMC6200133
mice Asxl1Y588XTg leukemic mouse model intraperitoneal injection 50 mg/kg 5 times per week for 5 weeks Reduced leukemic cell engraftment and tumor burden PMC10760961
mice orthotopic lung and ovarian cancer models intraperitoneal injection 50 mg/kg once daily for 4 weeks GSK-J4 significantly prolonged the survival of mice with SMARCA4-defective lung and ovarian tumors and reduced tumor growth PMC8280185
mice PDE model intraperitoneal injection 100 mg/kg daily from GD12 until labor GSK-J4 treatment significantly restored the trabecular area and Osterix+ cell area in the metaphyseal bone of PDE young mice offspring, indicating that GSK-J4 alleviates the negative impact of PDE on osteoprogenitor proliferation and bone development by inhibiting H3K27me3 demethylation. PMC11604782
Athymic mice SF8628 K27M DIPG xenograft model Intraperitoneal injection 100 mg/kg Once daily for 10 consecutive days GSK-J4 monotherapy significantly inhibited tumor growth and extended survival, and the combination therapy with radiation outperformed monotherapy. PMC6744979
nude mice osteosarcoma xenograft model intraperitoneal injection 50 mg/kg once daily until the end of the experiment To evaluate the effect of GSK-J4 on the osteosarcoma xenograft model, the results showed that GSK-J4 combined with cisplatin significantly reduced the size and weight of tumors and enhanced tumor cell apoptosis. PMC6335728

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

11.01mL

2.20mL

1.10mL

22.03mL

4.41mL

2.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories